Evidence map›Paper›PMID 25034157›Full record

ReviewRheumatic diseases clinics of North America2014

Pathogenesis and treatment of atherosclerosis in lupus.

Maureen McMahon, Brian Skaggs

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Rheumatic diseases clinics of North America, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Type-I interferons in atherosclerosis.The Journal of experimental medicine · 2020
    Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Maureen McMahonDivision of Rheumatology, David Geffen School of Medicine, University of California, Los Angeles, 1000 Veteran Avenue, Room 32-59, Los Angeles, CA 90095, USA. Electronic address: mmcmahon@mednet.ucla.edu.
Brian SkaggsDivision of Rheumatology, David Geffen School of Medicine, University of California, Los Angeles, 1000 Veteran Avenue, Room 32-59, Los Angeles, CA 90095, USA.
University of California, Los Angeles · US

Funding

The PREDICTS risk score for increased atherosclerosis and disease activity in SLER01AR063754 · NIAMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MCMAHON, MAUREEN A · 2014 to 2018
$2.8M
NIAMS NIH HHS R01 AR063754
6 · The paper itself

Abstract

The prevalence of atherosclerosis (ATH) is higher in patients with systemic lupus erythematosus (SLE) and occurs at an earlier age. The lupus-related factors that account for this increased risk are likely numerous and related to the factors described in this article. Identifying of at-risk subjects and increasing the understanding of pathogenesis of ATH in SLE is critical for improving the quality of care and improving mortality in this vulnerable population.

Indexed as

AtherosclerosisCardiovascular DiseasesLipid MetabolismLupus Erythematosus, SystemicAge FactorsBiomarkersCytokinesDisease ManagementHumansOutcome Assessment, Health CarePrevalenceRisk AssessmentRisk FactorsBiomarkersCytokinesAtherosclerosisCardiovascular diseasesCytokineProinflammatory lipidsSystemic lupus erythematosus

Identifiers

PMID25034157
PMCPMC6152881
OpenAlexW2106489185

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.